Arisaph Pharmaceuticals and Royalty Pharma Announce Monetization and Amendment of DPP-IV License Agreement

Boston, MA – August 11, 2011 – Arisaph Pharmaceuticals, Inc. (“Arisaph”) and Royalty Pharma announced today the closing of a transaction valued up to $26.25 million.

Source: Original Article